Markets Stocks Economy Crypto Earnings Banking Energy
Home› Stocks› Feature
Stocks · Exclusive

J&J's $2.2B Ollin Buy Shifts Retina Drug Trial Risk to Blackstone

J&J's $2.2B Ollin Buy Shifts Retina Drug Trial Risk to Blackstone
Stocks · 2026
Photo · Marcus Devlin for Daily Digest Invest
By Marcus Devlin Equities Correspondent Nov 16, 2026 4 min read

Johnson & Johnson is making a big bet on a new eye treatment, agreeing to buy biotech firm Ollin Biosciences for $2.2 billion upfront. The deal also brings in Blackstone Life Sciences, which will provide $750 million to help fund the late-stage clinical trials needed for regulatory approval.

The centerpiece is OLN324, an experimental drug designed to treat vision-threatening conditions like wet age-related macular degeneration and diabetic macular edema. These are common causes of blindness in older adults, and treatments that work better or last longer than current options could capture a large market.

What is OLN324?

OLN324 is a type of drug called a bispecific antibody. Unlike traditional antibodies that bind to one target, bispecific antibodies are engineered to attach to two different targets at once. In this case, the drug is designed to block two pathways that drive abnormal blood vessel growth in the eye—the underlying problem in wet AMD and diabetic macular edema.

Current standard treatments, such as Eylea or Lucentis, require frequent injections into the eye—sometimes every month or two. A drug that could extend the time between injections would be a major convenience for patients and could reduce the burden on healthcare systems. That's the potential payoff J&J is chasing.

The financial structure: sharing risk and reward

Phase 3 trials are the final and most expensive stage of drug development before a company can seek approval from regulators like the FDA. These studies can cost hundreds of millions of dollars and take years to complete. They are also all-or-nothing: a successful trial can lead to a blockbuster product, while a failure can wipe out years of investment.

By bringing in Blackstone Life Sciences, J&J is offloading part of that financial risk. Blackstone will fund $750 million of the Phase 3 program, which includes trials for both wet AMD and diabetic macular edema. In return, Blackstone will receive milestone payments if the drug hits certain regulatory and sales targets, plus single-digit royalties on future sales.

This structure is common in biotech dealmaking. It allows a large pharma company to limit its near-term spending and protect its income statement from the full cost of a risky trial. But it also means giving up a slice of future profits. If OLN324 becomes a top-selling drug, J&J will have to share some of that upside with Blackstone.

What it means for investors

For J&J shareholders, the deal is a calculated trade-off. The company is paying $2.2 billion upfront—a significant sum, but one that buys control of a promising asset. By having Blackstone fund the Phase 3 trials, J&J avoids a large hit to its cash flow and earnings in the near term. That can be appealing to investors who prefer steady financial results over big swings.

However, the deal also signals that J&J is willing to share future profits to reduce current risk. If OLN324 succeeds, the milestone payments and royalties to Blackstone will reduce the net revenue J&J keeps. That's the price of shifting risk.

For everyday investors, this deal is a reminder that pharma M&A isn't just about science—it's also about financial engineering. Companies often structure deals to manage their own balance sheets, and that can affect how much they ultimately earn from a new drug.

The broader context: J&J has been focusing on high-growth areas like oncology and immunology, but eye care remains a key franchise. The company already sells contact lenses and surgical equipment for eye procedures. Adding a potential blockbuster retina drug could strengthen that division.

Investors will be watching for updates on OLN324's Phase 3 trials, which are expected to begin soon after the deal closes. Any positive data could boost J&J's stock, while a setback could raise questions about the $2.2 billion price tag.

For now, the deal highlights a growing trend: big pharma partnering with investment firms to share the cost and risk of late-stage drug development. It's a way to keep innovation going without betting the whole company on a single trial.

More from this story

Next article · Don't miss

TPG in talks to take BILL Holdings private, Reuters reports

TPG is in talks to take BILL Holdings private, potentially at a premium, after activist investors pushed for changes. The news sent BILL shares up nearly 13% to a 52-week high.

Read the story →
TPG in talks to take BILL Holdings private, Reuters reports